Pharming Group Nv (PHAR) has released an update.
Pharming Group N.V. reported a robust first quarter in 2024, with revenues soaring by 31% to $55.6 million, largely due to the successful U.S. launch of Joenja® and solid growth in RUCONEST® sales. The company remains on target to achieve its annual revenue projection of $280-295 million, underpinned by a strong cash position of $203.5 million. Pharming is also advancing regulatory efforts and clinical trials to expand leniolisib’s market and prepare for its pediatric approval and additional indications in primary immunodeficiency disorders.
For further insights into PHAR stock, check out TipRanks’ Stock Analysis page.
